Search
Search Results
##search.searchResults.foundPlural##
-
INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER
3120PDF: 898HTML: 2922 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
1956PDF: 1566HTML: 344 -
NUTRITIONALLY VARIANT STREPTOCOCCI BACTEREMIA IN CANCER PATIENTS: A RETROSPECTIVE STUDY, 1999-2014
2009PDF: 957HTML: 4045Cover Letter: 204Figure 1: 200Figure 2: 209Table 1: 184 -
ESCHERICHIA COLI: AN IMPORTANT PATHOGEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
1748PDF: 685HTML: 2082Untitled: 186Untitled: 137Untitled: 151Untitled: 137Untitled: 144Untitled: 160Untitled: 166 -
TRANSCRIPTOME ANALYSIS OF BETA-CATENIN-RELATED GENES IN CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS FROM PATIENTS WITH AML Transcriptome analysis of beta-catenin-related genes in AML
942PDF: 1066Suppl. Files: 548HTML: 71 -
CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES
1815PDF: 813HTML: 1212 -
PROLIFERATION AND APOPTOSIS OF B-CELL LYMPHOMA CELLS UNDER TARGETED REGULATION OF FOXO3 BY miR-155 miR-155, FOXO3, B-cell lymphoma, proliferation, apoptosis, clinical characteristics
668PDF: 52HTML: 126 -
DIAGNOSTIC VALUE OF BRONCHOALVEOLAR LAVAGE IN LEUKEMIC AND BONE MARROW TRANSPLANT PATIENTS: THE IMPACT OF ANTIMICROBIAL THERAPY
1891PDF: 782HTML: 2187Table 1: 155Table 2: 170Table 3: 166Table 4: 171Table 5: 167Tble 6: 161Cover Letter: 182Greene Tab.7: 168 -
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
2702PDF: 810HTML: 6491Untitled: 203Untitled: 167Untitled: 163Untitled: 186 -
NF- ?B Essential Modulator Deficiency Leading to Disseminated Cutaneous Atypical Mycobacteria
1609PDF: 1048HTML: 10684Untitled: 158 -
TREATMENT OF CANCER IN THE OLDER AGED PERSON
1115PDF: 803HTML: 3341 -
SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival
1938PDF: 770HTML: 194 -
Tacrolimus Associated Posterior Reversible Encephalopathy Syndrome – A Case Series and Review
3450PDF: 1437HTML: 4260CoverLetter: 167Figure1: 173 -
THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition
1212PDF: 764HTML: 110 -
THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS
2491PDF: 697HTML: 2280 -
INCREASE IN CANDIDA PARAPSILOSIS CANDIDEMIA IN CANCER PATIENTS
1665PDF: 1038HTML: 223 -
A Case of Rupioid Syphilis Masquerading as Aggressive Cutaneous Lymphoma
2115PDF: 915HTML: 5016Cover Letter: 147Figure 2: 138Figure 1: 148Figure 3: 164Figure 4: 144Figure Legend: 160Table 1: 161Table 2: 156Table 3: 155 -
Bordetella Bronchiseptica in the Immunosuppressed Population – A Case Series and Review.
2344PDF: 1241HTML: 1713CoverLetter: 157 -
DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA Downregulation of Scd-1 in Chronic Myeloid Leukemia
1209PDF: 1126HTML: 419 -
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3414PDF: 2320HTML: 1401 -
CURRENT KNOWLEDGE ON HIV-ASSOCIATED PLASMABLASTIC LYMPHOMA
2490PDF: 1562HTML: 2333Table1: 172 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3485PDF: 830HTML: 6692 -
CROCIN PROMOTES APOPTOSIS IN HUMAN EBV-TRANSFORMED B-LYMPHOCYTE VIA INTRINSIC PATHWAY CROCIN PROMOTES APOPTOSIS IN EBV-TRANSFORMED LCL
1152PDF: 437HTML: 129 -
EVALUATION OF USING EMPIRIC GLYCOPEPTIDES IN ACCORDANCE WITH THE IDSA GUIDELINE IN HEMATOLOGIC MALIGNANCY PATIENTS WITH FEBRILE NEUTROPENIA Empiric glycopeptide use in neutropenic fever
1332PDF: 1001HTML: 205 -
Hsa-miR-5581-3p and hsa-miR-542-3p target the F8 gene in hemophilia A without F8 mutations F8 gene is regulated by miRNAs
1053PDF: 451HTML: 209 -
EBV-RELATED LYMPHOPROLIFERATIVE DISEASES: A REVIEW IN LIGHT OF NEW CLASSIFICATIONS EBV-RELATED LYMPHOPROLIFERATIVE DISEASES
3949PDF: 1509HTML: 791 -
OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
2151PDF: 997HTML: 1970Characteristic of study group: 174 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2501PDF: 769HTML: 5171 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
1507PDF: 771HTML: 136 -
Mantle cell lymphoma relapsing at the lymphedematous arm.
1632PDF: 667HTML: 3779 -
HIV-ASSOCIATED VENOUS THROMBOEMBOLISM
3750PDF: 1401HTML: 8481 -
Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio
2055PDF: 1509HTML: 247 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1581PDF: 1113HTML: 227 -
PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma
2337HTML: 248PDF: 814







